BBMRI - Biobanks, an under-used resource

Biobanks, an under-used resourceMark Divers

Karolinska Institutet Biobank och BBMRI.se

Vinnova-VR workshop , Stockholm, juni 2012

Forskningsinfrastruktur för industriella innovationer

But biobanking is hot!

• Big interest• >$1B technology spend per year

• Big population studies appeared• Hunt, deCode, UK Biobank, LifeGene, LifeLines, Kadoorie

• Big analysis transformation• Genetic and protein technologies

• Big discussion• Many hopes, many fears

2

Growing impact on medical research Huge public health opportunity

What is a biobank?

• Organiserad collection of biological samples– Often human

• Archived long-term– Frozen: -20, -80, -190°C

• Searchable & accessible– Samples and data

• Used for research, development and healthcare– Described as gold-mine!

• Regulated by law

Biobank landscape of Sweden

• 579 Biobanks

Biobank landscape of Sweden – for healthcare

Tissue 114 M sampelsCells 28, 7 MBlood/plasma 4530000Serum 2200000DNA/RNA 69000Bone 110000Others 106000

Biobank landscape of Sweden – for research

Blood/Plasma 4,2 MSerum 2,3 MDNA/RNA 572000Tissue 51000Urin 230000Salivia 112000Other 47000

The biobanks of KI and BBMRI.se are a rich source of samples: 150 studies

Population cohorts• TwinGene, LifeGene,

EpiHealth• Karma, Stockhom-2Disease based studies• Cancer• CV• Neurological• Inflammatory• ImmunologicalQuality registers

A good climate for biobank-based research in Sweden

• Well-characterised population• personal number system

• systematic registries

• Track-record• Eg Swedish Twin Registry ”TwinGene”

• Large population cohorts emerged 2009• LifeGene, EpiHealth

• Long-term research impact

• Public support

But challenges too

• Fragmentation• Organisational• Logistic• Economic

• Complex ethico-legal landscape

EU BBMRI initiative: our chance to create biobanks of the future

• Technology: test and apply the best!

• Network: connect modern biobanks!

• Vision: 300 biobanks throughout EU

• Harmonise: evolve common standards!

• Add big public health value!

Swedish Science Research Council and KI fund BBMRI.se for 5 years

large-Scale Swedish Biobanking (SSB); a service for big national studies

Some biobank accounts May 2012Total KIBB BBMRI.se

# studies 150 140 10# samples 2 634 210 584 578 2 049 632# donors 233 950 153 201 80 749# DNA samples 197 519 138 963 58 556# withdrawals >225 000 >175 000 >50 000

Creating a BBMRI.se national network

13

Progressive build up in medical universities

• Goteborg node

• launch Jan 2012

• 1st project: Scapis

• Malmö node

• launch 1Q2012

• 1st projects: EpiHealth, MKC, MFM

• Linköping, Umeå, Uppsala to come

• Linköping launch 1H2013?

• Projects identified

Starting co-ordination with healthcare biobanking

Co-ordinated:• Sample format• Data format• Processes• Equipment & consumables• Access and use

Unifying Swedish biobanks further

University + Healthcare biobanks• National common infrastructure

– VR - SKL declaration

• Regional partnerships, eg– Uppsala biobank– Göteborg– Region Skåne– KI – SLL

Why are we biobanking?...

… to advance medical research!

• Combine with modern bio-analysis• Systematic• Statistical power

• Huge potential for public health

Study publications

GALLSTEN 4

PAIN 2

BAMSE 8

SCALE 15

Ekonomiskt beteende 2

TwinGene & Euroclot 13

HARMONY & SATSA 12

KTS 1

CAPS 40

Totalt 97

Emerging highlights

• Multiple Sclerosis

• TwinGene

• Broad

• Influenza Like Illnesses

• Prostate Cancer

What is the value of biobanking?...

Multiple Sclerosis research gives a great example*

• ~17K MS cases in Sweden• Many represented in our biobank• New therapy, Tysabri™

• Monoclonal antibody• Very effective, very expensive• Serious side effects in some (polyoma viral cross-reacton)

• Screen MS biobank for polyoma virus• Save big drug cost (200KKr/patient/yr)• Save some lives, improve others• Match a good drug to the right patients http://www.pharmatimes.com/Article/12-01-23/New_Tysabri_label_to_personalise_treatment.aspx

16

*T Olsson et al

Biobanking adds big valueClinical practice

Health economy

Drug development

Ethical credibility

Sample collection

Sample analysis

Data analysis

Better screening, diagnosis and treatment match

Better public health for lower cost

Increased trust and support

Matching patients to treatmentsEthical review

eg HPV, MS

eg MS, HIV, HPV

eg HPV

2012-01-03 Mark Divers

Biobanks for industrial innovation?

Discovery & Development• Pharmaceuticals

– Biomarkers– Patient subtyping– Metabolites– Safety profiling

• Diagnostics• …

19

Lab OperationsCarita RaskJaspal Singh

Cecilia AgardhPeter ArnerlövAnci CarmanPia Hillelson

Camilla LagerbergVian OsmanAmina Said

Anette SelanderJohanna Smith

Siwonne AnderssonEmma RidellWilliam Day

Valentina NovakKarin Lindqvist

Biobank ITEva Büren

Staffan BerghJonas Birgersson

Ulrika BohlinJesper Lind

Johan StenningerJosé Tapia

Anni ÅsbergNiclas Ahlin

Project coordinationAnders Brinne

Biobank DevelopmentGunnel Tybring

QualityAnette Petersson

Mirja Larsson

Acknowledgements

The LifeGene Crewincluding

Jens MattssonKicki KjaergaardMats ThurmanCamilla Björk

Thomas Bergman

The BBMRI CrewJoakim DillnerJan-Eric LittonMats Hansson

Göran HallmansUlf LandegrenJoakim Galli

Lars-Olof HanssonJoyce Carlsson

Lisen Arnheim-DahlströmSofie PetterssonMartin FranssonLoreana Norlin

Maria Anderberg

Others @ KIHenrik Grönberg

Per HallNancy PedersenRune FransonPer Spångeus

Customer RelationsTove Rylander-Rudqvist

Cecilia Björkdahl

The Biobank Crew

More infohttp://ki.se/kibiobankwww.bbmri.sewww.lifegene.se